# Retatrutide Research: Phase 2 and Phase 3 Trial Data, Mechanism, and Literature Review > Retatrutide research summaries — Phase 2 obesity, type 2 diabetes, MASLD trials, structural pharmacology, and the Phase 3 TRIUMPH/TRANSCEND programs. Fully cited. Key findings from every major retatrutide study — mechanism to outcomes, organized by trial. All figures cited. ## Start here: what Retatrutide research has established so far Retatrutide is a synthetic peptide that activates three hormone receptors at once — GIP, GLP-1, and glucagon. It is investigational: not approved, studied under clinical-trial conditions only. The research record runs from a Phase 1b pharmacokinetics study in 2022 through a Phase 3 trial in type 2 diabetes reported in 2026, with an ongoing Phase 3 obesity and outcomes program. Here is what the trials have measured: retatrutide produces large weight losses, significant blood-sugar reductions in diabetes, and dramatic liver-fat clearance in fatty liver disease. The mechanism behind all three outcomes is the same triple-receptor approach — GLP-1 and GIP handle glucose and appetite; glucagon adds energy burning. The Phase 3 data are still accumulating. Long-term cardiovascular and kidney outcomes are the open questions the current trials are designed to answer. Everything below is sourced to the peer-reviewed literature. The full citation list is on [Retatrutide references](/references). ## Structural pharmacology: how the molecule binds Cryo-EM structures resolved retatrutide simultaneously engaging GLP-1R, GIPR, and GCGR — the first structural confirmation of triple agonism at atomic resolution [3]. Relative potency versus native endogenous hormones: 8.9× at GIPR (superagonist), 0.3× at GCGR, 0.4× at GLP-1R. The extracellular loop 1 (ECL1) adopts a rigid alpha-helix in GLP-1R and GCGR but a flexible loop in GIPR — explaining the differential receptor engagement that makes retatrutide distinct from native GIP or GLP-1. The molecule is a 39-amino-acid peptide built on a GIP-based backbone, acylated with a C20 fatty diacid for albumin binding and extended plasma half-life. Molecular weight: 4731.33 Da; formula C221H342N46O68. The half-life of approximately 6 days, measured in Phase 1b PK studies [4], supports the once-weekly dosing schedule used across all trials. A 2026 mechanistic review characterized retatrutide's triple agonism as mimicking the pleiotropic nutrient-stimulated hormonal responses seen after bariatric surgery, with broad clinical utility across hepatic, cardiovascular, and metabolic domains — a paradigm shift from glucose-lowering alone [10]. ## Phase 1b: first-in-human pharmacokinetics and early efficacy (2022) The first-in-human Phase 1b trial enrolled 72 adults with type 2 diabetes (HbA1c 7.0–10.5%) in a multiple-ascending-dose design over 12 weeks [4]. Dose groups: 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg once weekly subcutaneous. Key PK finding: half-life approximately 6 days, consistent across dose groups, confirming the weekly dosing hypothesis. Placebo-adjusted weight loss at the highest-dose group: -8.96 kg (90% CI -11.16 to -6.75). Daily glucose reduction: -2.8 mmol/L at 3 mg. Treatment-emergent adverse events in 63% of participants, predominantly GI, mostly mild. The safety profile was characterized as acceptable — no serious adverse events related to the compound. This trial established the PK foundation for the Phase 2 program's dose-range selection. ## Phase 2 obesity trial: 48 weeks, n=338 (2023) The pivotal Phase 2 obesity trial (published in the New England Journal of Medicine, 2023) enrolled 338 adults with obesity or overweight with at least one comorbidity, over 48 weeks [1]. Doses: 1, 4, 8, or 12 mg once weekly subcutaneous. **Primary endpoint — weight change:** - 12 mg: -24.2% mean body weight vs -2.1% placebo - 8 mg: -17.3% - 4 mg: -8.7% - 1 mg: -3.7% At 12 mg, 26% of participants achieved ≥30% body weight loss. Adverse events: GI effects (nausea, diarrhea, vomiting) were dose-related and mostly mild to moderate. Dose-dependent heart rate increase peaking at week 24, mean 5–7 bpm at highest doses. Discontinuation due to adverse events: 18% at 12 mg. A review published in *Biomolecules* (2025) characterized the 24% weight loss as a step-change versus prior incretin therapies, representing the first Phase 2 data approaching bariatric-surgery-level outcomes [6]. ## Phase 2 type 2 diabetes trial: 36 weeks, n=281 (2023) A randomized double-blind Phase 2 trial in adults with type 2 diabetes and inadequate glycemic control on diet and exercise enrolled 281 participants across 0.5–12 mg stepwise escalation [2]. Published in *The Lancet*, 2023. **Primary endpoints at 24 weeks (HbA1c):** - 12 mg: -2.02% HbA1c vs -0.01% placebo - 8 mg: -1.83% **Secondary endpoints at 36 weeks (weight):** - 12 mg: -16.94% body weight vs -3.00% placebo No severe hypoglycemia in participants not on background insulin. Mild-to-moderate GI adverse events in 35% of participants. No deaths. The trial established glycemic and weight efficacy across a broad escalation range and confirmed the GI safety profile documented in Phase 1b. ## Phase 2 MASLD substudy: liver fat, 48 weeks, n=98 (2024) A Phase 2a substudy enrolled 98 participants with obesity or overweight and MASLD (metabolic dysfunction-associated steatotic liver disease) — defined as ≥10% liver fat by MRI-PDFF (magnetic resonance imaging proton density fat fraction), without type 2 diabetes [5]. Published in *Nature Medicine*, 2024. **Liver fat change at 24 weeks (relative):** - 12 mg: -82.4% relative reduction vs +0.3% placebo - 8 mg: -81.4% - 4 mg: -57.0% - 1 mg: -42.9% At 12 mg, 86% of participants reached normal liver fat (<5%) at 24 weeks. Reductions sustained to 48 weeks (-86.0% at 12 mg). This was published in the same year as emerging data on GLP-1-class therapies for MASH (metabolic-associated steatohepatitis) resolution [9], placing retatrutide in context as one of the most potent liver-fat-clearing compounds in the investigational pipeline. ## Phase 3 TRANSCEND-T2D-1 readout (2026) The first Phase 3 data published from the retatrutide program was TRANSCEND-T2D-1 (n=537 adults with type 2 diabetes), a 40-week randomized double-blind placebo-controlled trial [12]. Published in *The Lancet*, 2026. **Results at 40 weeks:** - Retatrutide 12 mg: HbA1c -1.94% vs -0.81% placebo; body weight -15.3% vs -2.6% placebo - Treatment discontinuation due to adverse events: 8.5% at 12 mg vs 2.2% placebo - No severe hypoglycemia - Adverse events: predominantly mild-to-moderate GI These results confirm Phase 2 findings at Phase 3 scale in a diabetes population and represent the first regulatory-grade trial data for retatrutide. The TRIUMPH obesity program and cardiovascular/kidney outcomes trials remain ongoing. ## Retatrutide vs tirzepatide Tirzepatide is a dual GIP/GLP-1 agonist that is approved for type 2 diabetes and obesity. Retatrutide adds glucagon receptor agonism to that dual foundation, creating the triple-agonist profile. In Phase 2 data, retatrutide 12 mg/48 weeks produced -24.2% body weight loss — higher than tirzepatide's Phase 3 peak of approximately -20–22% at the highest approved dose. Retatrutide has progressed to Phase 3 with an active-comparator arm versus tirzepatide in the TRIUMPH program, which will provide the first randomized head-to-head data [8]. Until that reports, the cross-trial comparison is hypothesis-generating, not definitive — study populations, escalation schedules, and trial durations differ. A 2026 review concluded that retatrutide achieves weight reduction currently unmatched in the oral/injectable pipeline, but that the class-level limitation — weight regain upon discontinuation — applies here as well [14]. The glucagon arm adds energy expenditure, but whether it changes the long-term metabolic set point is unknown. ## Is retatrutide fda approved No. Retatrutide is not FDA-approved and not approved by any regulatory agency as of mid-2026. It is an investigational compound in Phase 3 clinical trials. The TRIUMPH-1/2 obesity trials and the TRANSCEND series in type 2 diabetes are ongoing. An NDA (New Drug Application) has not been submitted to the FDA. A regulatory timeline has not been publicly confirmed by Eli Lilly as of the current date. No retatrutide product can be legally prescribed or purchased as a medication in the United States or elsewhere. ## Retatrutide availability Retatrutide is not available by prescription. It is accessible only through participation in clinical trials. Outside of trials, gray-market research-labeled material circulates in unregulated channels, but such material carries unverified identity, purity, and sterility risks — it cannot be confirmed to be authentic retatrutide. Clinical trial enrollment can be explored at ClinicalTrials.gov by searching NCT numbers in the TRIUMPH and TRANSCEND programs. ## When will retatrutide be available No approval date has been confirmed. Phase 3 trials are ongoing as of 2026. Regulatory submission would follow Phase 3 completion and data analysis — a process that typically takes additional years after the last trial reports. Estimates circulating in media are speculative. This site will not publish timeline projections unsupported by official filings. --- An independent briefing on published investigational trial data — not a clinic, not a formulary, not a recommendation.